Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6954990 | 0.89 | CHRM2 (0.34) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL14764516 | 0.81 | CHRM2 (0.41) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL8329335 | 0.81 | CHRM2 (0.37) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL8329981 | 0.81 | CHRM2 (0.37) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL5777875 | 0.78 | CHRNB2 (0.30) | — | |
| SCHEMBL9942309 | 0.76 | — | — | |
| SCHEMBL14324896 | 0.76 | — | — | |
| SCHEMBL5537141 | 0.75 | CHRNA4 (0.43) | NR1H2 | |
| SCHEMBL3397031 | 0.75 | CHRNA4 (0.43) | NR1H2 | |
| SCHEMBL4435193 | 0.74 | CHRM2 (0.33) | CHRM2CHRM1CHRM3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2132193-B1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-10-24 | — | — | EP | disclosed |
| EP-1975165-A1 | Substituted pyrrolidinamides, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-10-01 | — | — | EP | disclosed |